Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 3/20 | 0.39 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | REN | P00797 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3597380 | 1.00 | ATM (0.42) | ATMCYP3A4SYKAPPCTSS | |
| SCHEMBL3597383 | 1.00 | ATM (0.42) | ATMCYP3A4SYKAPPCTSS | |
| SCHEMBL15005688 | 0.75 | ROCK2 (0.36) | CYP3A4TRPV1 | |
| SCHEMBL27129004 | 0.70 | CYP3A4 (0.48) | ATMCYP3A4APPCTSSCTSL | |
| SCHEMBL27032731 | 0.70 | CYP3A4 (0.48) | ATMCYP3A4APPCTSSCTSL | |
| SCHEMBL30639506 | 0.68 | CYP3A4 (0.47) | ATMCYP3A4APP | |
| SCHEMBL29096836 | 0.68 | CYP3A4 (0.47) | ATMCYP3A4APP | |
| SCHEMBL29828650 | 0.68 | CYP3A4 (0.47) | ATMCYP3A4APP | |
| SCHEMBL29097261 | 0.68 | CYP3A4 (0.48) | ATMCYP3A4APP | |
| SCHEMBL30639635 | 0.68 | CYP3A4 (0.48) | ATMCYP3A4APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2118102-B1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-8207180-B2 | Tricyclic indoles and (4,5-dihydro) indoles | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2012-06-26 | — | — | US | disclosed |
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075998-A1 | TRICYCLIC INDOLES AND (4,5-DIHYDRO) INDOLES | CDC7, CDK7, CDK17 | ATM 708/4885CYP3A4 1771/4885SYK 2710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.